Cellceutix jumps on QIDP tag
23 min ago1:23 p.m. Dec. 8, 2014
- Seeking Alpha
Cellceutix Brilacidin IND effective, Phase 2 to begin
9:31 a.m. Oct. 13, 2014
- Seeking Alpha
Regulatory Support Creates Opportunity For Antibiotic Makers Otonomy And Cellceutix
9:02 a.m. Sept. 25, 2014
- Seeking Alpha
Update: Cellceutix Calls Out To President Obama About Brilacidin
2:38 p.m. Sept. 21, 2014
- Seeking Alpha
10-K: CELLCEUTIX CORP
12:53 p.m. Sept. 15, 2014
- Edgar Online - (EDG = 10Q, 10K)
Update: Cellceutix's Antibiotic Brilacidin Should Move Share Price Before Kevetrin Or Prurisol
2:06 a.m. Sept. 14, 2014
- Seeking Alpha
The Antibiotic Resistance Triple Threat
1:05 p.m. Sept. 4, 2014
- Seeking Alpha
Cellceutix completes enrollment in Brilacidin trial
8:45 a.m. Aug. 19, 2014
- Seeking Alpha
Did The Medicines Company Trump Cellceutix And Others In A $1B-Plus Skin Infection Market?
10:38 a.m. Aug. 14, 2014
- Seeking Alpha
10-Q: CELLCEUTIX CORP
9:15 a.m. May 12, 2014
- Edgar Online - (EDG = 10Q, 10K)
Huge Opportunities Are Now Possible Due To Market Inefficiencies In Valuing Antibiotic Companies Such As Cubist, Durata, And Cellceutix
9:34 a.m. April 25, 2014
- Seeking Alpha
10-Q: CELLCEUTIX CORP
4:09 p.m. Feb. 10, 2014
- Edgar Online - (EDG = 10Q, 10K)
Cellceutix Is Significantly Undervalued Considering The Value Of Brilacidin
9:31 a.m. Jan. 28, 2014
- Seeking Alpha
Cellceutix Corp.: A Biotech With High Risk But High Reward
3:17 p.m. Jan. 2, 2014
- Wall St. Cheat Sheet
Cellceutix: An Undiscovered Company Set To Rise In 2014
9:06 a.m. Dec. 16, 2013
- Seeking Alpha
3 Innovative Biotech Companies Poised To Shine At TAP Partnership Conference
5:38 a.m. Nov. 19, 2013
- Seeking Alpha
10-Q: CELLCEUTIX CORP
5:06 p.m. Nov. 8, 2013
- Edgar Online - (EDG = 10Q, 10K)
10-K: CELLCEUTIX CORP
3:01 p.m. Sept. 30, 2013
- Edgar Online - (EDG = 10Q, 10K)
10-Q: CELLCEUTIX CORP
1:18 p.m. May 20, 2013
- Edgar Online - (EDG = 10Q, 10K)
Interview with CEO of Cellceutix Corporation: Leo Ehrlich
8:57 a.m. Nov. 15, 2011
- GuruFocus.com
Cellceutix Antibiotic Brilacidin Receives QIDP Designation From FDA
7:01 a.m. Today7:01 a.m. Dec. 8, 2014
- Marketwired
Cellceutix: December to Be Momentous Month in Company's History
7:02 a.m. Nov. 24, 2014
- Marketwired
These Medical Stocks Are Reaching A Fever Pitch Following Midterm Elections
9:54 a.m. Nov. 12, 2014
- ACCESSWIRE
Patient Enrollment in Cellceutix Phase 2 Clinical Trial of
Brilacidin-OM for Oral Mucositis Targeted to Begin in December 2014
7:01 a.m. Nov. 11, 2014
- Marketwired
Cellceutix's New Chief Operating Officer Dr. James Alexander
Addresses Shareholders
6:00 a.m. Oct. 31, 2014
- Marketwired
Cellceutix Announces Positive Top-Line Data From Phase 2b ABSSSI
Trial; Single-Dose Brilacidin Comparable to 7-Days of Daptomycin
10:52 a.m. Oct. 23, 2014
- Marketwired
Cellceutix Investigational New Drug (IND) Application Becomes
Effective, Selects First Site for Phase 2 Clinical Trial of New
Treatment for Oral Mucositis
8:02 a.m. Oct. 13, 2014
- Marketwired
Cellceutix Provides Update to Shareholders
11:30 a.m. Sept. 24, 2014
- Marketwire
Cellceutix to President Obama: We Have the Tools and Will Rise Up to
the Challenge to Prevent Antibiotic Resistant Bacteria Becoming a
Serious Threat to Public Health
6:15 a.m. Sept. 19, 2014
- Marketwire
Cellceutix Provides Initial Observations of Completed ABSSSI Phase 2b
Trial; Company Submits Investigational New Drug Application to FDA
for Phase 2 Trial of Brilacidin-OM for Oral Mucositis
2:01 p.m. Sept. 9, 2014
- Marketwire
Cellceutix to Present at Rodman & Renshaw's 16th Annual Global
Investment Conference
10:17 a.m. Sept. 5, 2014
- Marketwire
Cellceutix Appoints Dr. Barry Schechter to Board of Directors as
Company Focuses on Meeting Requirements for Stock Exchange Uplisting
6:01 a.m. Sept. 2, 2014
- Marketwire
Cellceutix Completes Enrollment in Phase 2b Clinical Trial of
Brilacidin for Acute Bacterial Skin and Skin Structure Infections
(ABSSSI)
7:31 a.m. Aug. 19, 2014
- Marketwire
Cellceutix Prepares for Phase 2 Clinical Trial of Brilacidin-OM for
Oral Mucositis
6:01 a.m. Aug. 11, 2014
- Marketwire
Cellceutix Anti-Psoriasis Drug Prurisol Meets Primary Endpoint of
Clinical Trial
5:04 a.m. Aug. 8, 2014
- Marketwire
Cellceutix Believes Brilacidin on Track to Help U.S. Avoid Falling
Into Post-Antibiotic Era; Completion of Enrollment in Phase 2b Trial
for Acute Bacterial Skin and Skin Structure Infections Expected This
Month
6:01 a.m. Aug. 4, 2014
- Marketwire
Cellceutix Announces Breakthrough in the Formulation of Its Novel
Antibiotic Brilacidin(TM), Plans Studies to Treat Diabetic Foot
Ulcers
6:01 a.m. July 14, 2014
- Marketwire
Cellceutix Brilacidin ABSSSI Trial Gets Positive Review by Data
Safety Monitoring Board; Best Possible Outcome, No Treatment-Related
Serious Adverse Events (SAEs)
6:00 a.m. July 7, 2014
- Marketwire
Cellceutix Anti-Fungal Compounds Awarded $1.5 Million SBIR Grant
6:01 a.m. June 23, 2014
- Marketwire
Cellceutix Clinical Trial of Anti-Cancer Drug Kevetrin Entering
Eighth Cohort
6:01 a.m. June 16, 2014
- Marketwire